Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 03.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 09.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 02.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 30.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 06.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 28.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
Stammdaten
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Unternehmen & Branche
| Name | TELA Bio, Inc. |
|---|---|
| Ticker | TELA |
| CIK | 0001561921 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | 208077520 |
|---|---|
| ISIN | US2080775206 |
| Typ | Common Stock |
| Marktkapitalisierung | 34,7 Mio. USD |
| Beta | 0,99 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 80,275,000 | -38,831,000 | -0.83 | 81,418,000 | 6,313,000 |
| 2025-09-30 | 10-Q | 20,689,000 | -8,603,000 | -0.19 | 61,587,000 | 1,557,000 |
| 2025-06-30 | 10-Q | 20,197,000 | -9,923,000 | -0.22 | 67,537,000 | 9,184,000 |
| 2025-03-31 | 10-Q | 18,520,000 | -11,264,000 | -0.25 | 77,251,000 | 18,123,000 |
| 2024-12-31 | 10-K | 69,300,000 | -37,841,000 | -1.33 | 86,570,000 | 28,458,000 |
| 2024-09-30 | 10-Q | 18,957,000 | -10,372,000 | -0.42 | 53,016,000 | -6,272,000 |
| 2024-06-30 | 10-Q | 16,091,000 | -12,600,000 | -0.51 | 60,204,000 | 2,870,000 |
| 2024-03-31 | 10-Q | 16,603,000 | -5,661,000 | -0.23 | 71,837,000 | 14,384,000 |
| 2023-12-31 | 10-K | 58,453,000 | -46,664,000 | -2.04 | 78,048,000 | 18,881,000 |
| 2023-09-30 | 10-Q | 15,052,000 | -10,957,000 | -0.45 | 87,317,000 | 30,552,000 |
| 2023-06-30 | 10-Q | 14,494,000 | -10,790,000 | -0.46 | 94,386,000 | 40,005,000 |
| 2023-03-31 | 10-Q | 11,909,000 | -12,027,000 | -0.63 | 58,788,000 | 3,141,000 |
| 2022-12-31 | 10-K | 41,418,000 | -44,296,000 | -2.72 | 67,855,000 | 14,305,000 |
| 2022-09-30 | 10-Q | 11,159,000 | -10,714,000 | -0.64 | 79,563,000 | 23,301,000 |
| 2022-06-30 | 10-Q | 10,406,000 | -12,741,000 | -0.88 | 51,333,000 | -1,542,000 |
| 2022-03-31 | 10-Q | 8,231,000 | -10,862,000 | -0.75 | 55,355,000 | 10,038,000 |
| 2021-12-31 | 10-K | 29,463,000 | -33,276,000 | -2.30 | 62,544,000 | 20,098,000 |
| 2021-09-30 | 10-Q | 7,654,000 | -8,266,000 | -0.57 | 68,809,000 | 27,729,000 |
| 2021-06-30 | 10-Q | 7,558,000 | -8,255,000 | -0.57 | 73,799,000 | 34,965,000 |
| 2021-03-31 | 10-Q | 5,877,000 | -8,136,000 | -0.56 | 78,319,000 | 41,691,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-11-17 | EW HEALTHCARE PARTNERS FUND 2, L.P. | 10% Owner | Open Market Purchase | 3,604,000 | 1.11 | 4,000,440.00 | +100,0% |
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.03.2024. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| AWM Investment Company, Inc. | 589,963 | 3,345,090 | 100.00 |